American Association for Pediatric Ophthalmology and Strabismus

Progressive myopia in children: What Eye Care Providers should know

Why Does Myopia Matter?

- According to the largest observational study published to date, myopia now affects approximately one-third of children globally, and this figure is projected to continue to increase significantly in the coming years, to over 740 million cases by 2050.[1] The American Academy of Ophthalmology (AAO) has reported that the estimated prevalence of myopia in North America in 2020 is 42.1%, and it is predicted to increase to 58.4% by 2050.[2]
- Myopia increases the risk of ocular complications. Even moderate myopia (-3D or higher) is associated with higher lifelong risks of retinal detachments, glaucoma, and cataracts. High myopia -6.0 Diopters or higher has been found to be associated with a 20 times higher risk of retinal detachments along with glaucoma, early cataracts and myopic degeneration. These risks of future myopic complications do not go away if the child goes on to get LASIK or other refractive surgeries later in life because the heightened risks are due to axial elongation.

How Can We Slow Myopia Progression?

While myopia cannot usually be reversed, there are several strategies that have been shown to slow down its progression and slow axial elongation.

1. **Environmental Changes**
   - **Increased Outdoor Time**: Many studies have shown that children who spend more time outdoors with exposure to natural light have less myopic progression.[3-5] Children should aim to have at least 2 hours outside per day.
   - **Limiting Digital Devices**: Increased screen time has also been linked to an increase in childhood myopia.[6-9] Children should avoid prolonged screen time for entertainment and should be encouraged to use larger devices held farther away from their eyes and faces (i.e. television on opposite wall would be preferable to a handheld tablet). Ideally at school and at home, children should follow the **20-20-20 rule:** every 20 minutes of near work, look at something 20 feet away for 20 seconds.

2. **Optical Strategies**
   - **Defocus Spectacles**: These spectacle lenses are designed to have a central zone that corrects the myopia and multiple small lens segments in the periphery of the lenses to create a defocus on the peripheral retina. This peripheral defocus has been found to slow progression of myopia and axial length. The Essilor Stellest

spectacles have recently been FDA approved in the United States for slowing myopic progression, and there are other brands available outside the United States that offer similar designs as well.[10-13] Children may not be candidates if their refraction is too high or if they have strabismus.

- **Dual Focus Soft Contact Lenses**: These are soft contact lenses worn during the day with different focus zones built into the lens designs. The central zone allows good vision and corrects the child's myopia while the outer zones create a peripheral defocus that slows eye growth and myopia progression, like the defocus spectacles. MiSight contact lenses by CooperVision are FDA approved daily wear contact lenses for slowing myopic progression and are available in a variety of powers.[14-17] Standard multifocal contacts can also be tried as an off-label alternative.
- **Orthokeratology ("OrthoK"):** These are special rigid gas permeable contact lenses worn overnight to reshape the cornea. This reshaping can provide clear vision during the day without glasses or contact lenses but because children sleep in the rigid contact lens, there is increased risk of permanent ocular surface changes, corneal infections like ulcers, scarring, and inflammation which can lead to permanent loss of vision. [18-22]

3. **Pharmacologic**

- **Low Dose Atropine Eyedrops**: Dilute atropine (usually 0.01% to 0.05%) used on a nightly basis have been shown to slow eye growth and myopia progression in children. Low dose atropine eyedrops have been well studied and are typically well tolerated with no long-term side effects or complications.[23-32] Although blurred vision at near, photophobia, pupil dilation and anisocoria are known side effects of atropine, diluting the atropine does mitigate these effects. The FDA has yet to approve a commercially made dilute atropine in the United States so drops are still compounded by specialty pharmacies in the United States.

Which Strategy is Best?

There is no one treatment that we know reverses or prevents any of the potential long-term risks of high myopia. Many of these treatments above are not covered by insurance so any treatment a family chooses may need to be paid out of pocket and potentially for several years for maximum potential benefit. There are also some serious risks to the treatments such as bacterial keratitis and corneal ulcers from contact lenses (especially ortho-K lenses) and blurring and photophobia from dilute atropine and potential self-limited anisocoria. Behavioral and environmental changes are the only free and no risk option we can recommend at this time. However, with regular monitoring and supervision of these treatments by their pediatric eye care provider, most of these treatments can be well tolerated and safe for many children. It is important for any decision regarding myopia control to be made together by the parents, eye care provider and child to determine the best treatment strategy for each child.

References:

1. Liang J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. *Br J Ophthalmol*. 2024;109(3).
2. Holden B, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. *Ophthalmology*. 2016;123(5).
3. Guo Y, Liu LJ, Tang P, Lv YY, Feng Y, Xu L, Jonas JB. Outdoor activity and myopia progression in 4-year follow-up of Chinese primary school children: The Beijing Children Eye Study. PLoS One. 2017 Apr 27;12(4):e0175921. doi: 10.1371/journal.pone.0175921. PMID: 28448513; PMCID: PMC5407804.
4. Rose KA, Morgan IG, Ip J, Kifley A, Huynh S, Smith W, Mitchell P. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008 Aug;115(8):1279-85. doi: 10.1016/j.ophtha.2007.12.019. Epub 2008 Feb 21. PMID: 18294691.
5. Martinez-Perez C, Sanchez-Tena MA, Sánchez-González JM, Villa-Collar C, Alvarez-Peregrina C. Influence of outdoor time on the spherical equivalent and axial length in childhood myopia: A meta-analysis. Acta Ophthalmol. 2025 Dec;103(8):864-878. doi: 10.1111/aos.17478. Epub 2025 Mar 11. PMID: 40066935; PMCID: PMC12604451.
6. Hu T, Wu R, Wang W, Li H, Peng X. Analysis of factors related to the development of ocular biometric parameters in Chinese children aged 6-10 years: a cross-sectional study. BMJ Open. 2024 Feb 6;14(2):e080066. doi: 10.1136/bmjopen-2023-080066. PMID: 38320844; PMCID: PMC10859994.
7. Wu F, Tham YC, Sabanayagam C, Saw SM. From evidence to action: Public health approaches to reducing screen time and mitigating myopia risk. Asia Pac J Ophthalmol (Phila). 2025 Mar-Apr;14(2):100177. doi: 10.1016/j.apjo.2025.100177. Epub 2025 Feb 26. PMID: 40021087.
8. Foreman J, Salim AT, Praveen A, Fonseka D, Ting DSW, Guang He M, Bourne RRA, Crowston J, Wong TY, Dirani M. Association between digital smart device use and myopia: a systematic review and meta-analysis. Lancet Digit Health. 2021 Dec;3(12):e806-e818. doi: 10.1016/S2589-7500(21)00135-7. Epub 2021 Oct 5. PMID: 34625399.
9. Lanca C, Yam JC, Jiang WJ, Tham YC, Hassan Emamian M, Tan CS, Guo Y, Liu H, Zhong H, Zhu D, Hu YY, Saxena R, Hashemi H, Chen LJ, Wong TY, Cheng CY, Pang CP, Zhu H, Pan CW, Liang YB, Fotouhi A, Bi HS, Jonas JB, Saw SM; Asian Eye Epidemiology Consortium (AEEC). Near work, screen time, outdoor time and myopia in schoolchildren in the Sunflower Myopia AEEC Consortium. Acta Ophthalmol. 2022 May;100(3):302-311. doi: 10.1111/aos.14942. Epub 2021 Jun 17. PMID: 34142457.
10. Wygnanski-Jaffe T, Shulman S, Gottesman N, Feit N, Corcos Y, Zvibach O, Stolovitch C. New design peripheral defocus spectacle lens vs. single-vision for slowing myopia progression in children: randomized controlled trial. Sci Rep. 2025 Nov 13;15(1):39861. doi: 10.1038/s41598-025-23501-1. PMID: 41233497; PMCID: PMC12615687.
11. Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, Wang C, Li Y, Lim EW, Spiegel DP, Drobe B, Chen H. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol. 2022 May 1;140(5):472-478. doi: 10.1001/jamaophthalmol.2022.0401. PMID: 35357402; PMCID: PMC8972151.
12. Li X, Huang Y, Liu C, Chang X, Cui Z, Yang Q, Drobe B, Bullimore MA, Chen H, Bao J. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye Vis (Lond). 2025 Mar 5;12(1):10. doi: 10.1186/s40662-025-00427-3. PMID: 40038807; PMCID: PMC11881363.
13. Huang Y, Li X, Wang Y, Drobe B, Chen H, Bao J. Effect of spectacle lenses with highly aspherical lenslets on changes in peripheral eye length and asymmetry. Ophthalmic Physiol Opt. 2025 Jul;45(5):1040-1048. doi: 10.1111/opo.13500. Epub 2025 Mar 29. PMID: 40156552; PMCID: PMC12153024.
14. Pomeda AR, Pérez-Sánchez B, Cañadas Suárez MDP, Prieto Garrido FL, Gutiérrez-Ortega R, Villa-Collar C. MiSight Assessment Study Spain: A Comparison of Vision-Related Quality-of-Life Measures Between MiSight Contact Lenses and Single-Vision Spectacles. Eye Contact Lens. 2018 Nov;44 Suppl 2:S99-S104. doi: 10.1097/ICL.0000000000000413. PMID: 28719538.
15. Ruiz-Pomeda A, Pérez-Sánchez B, Valls I, Prieto-Garrido FL, Gutiérrez-Ortega R, Villa-Collar C. MiSight Assessment Study Spain (MASS). A 2-year randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):1011-1021. doi: 10.1007/s00417-018-3906-z. Epub 2018 Feb 3. PMID: 29396662.

16. Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567. doi: 10.1097/OPX.0000000000001410. PMID: 31343513.
17. Lumb E, Sulley A, Logan NS, Jones D, Chamberlain P. Six years of wearer experience in children participating in a myopia control study of MiSight® 1 day. Cont Lens Anterior Eye. 2023 Aug;46(4):101849. doi: 10.1016/j.clae.2023.101849. Epub 2023 May 6. PMID: 37156658.
18. Yang XD, He XY, Lyu Y, Wang WQ, Wan GM. Effects of wearing orthokeratology lenses for more than 5 years on the ocular surface of adolescents. Cont Lens Anterior Eye. 2026 Feb;49(1):102494. doi: 10.1016/j.clae.2025.102494. Epub 2025 Aug 23. PMID: 40849245.
19. Feng J, Gu Y, Wen Y, Wang Y, Wang J, Li A, Hao Y, Li Q, Wang W, Tian L, Jie Y. Influence of Overnight Orthokeratology on Ocular Surface and Blink Patterns in Children and Adolescents-A Prospective Cohort Study. Eye Contact Lens. 2025 Jun 6;51(9):375-379. doi: 10.1097/ICL.0000000000001197. PMID: 40489972; PMCID: PMC12363327.
20. Hiraoka T, Matsumura S, Hori Y, Kamiya K, Miyata K, Oshika T. Incidence of microbial keratitis associated with overnight orthokeratology: a multicenter collaborative study. Jpn J Ophthalmol. 2025 Jan;69(1):139-143. doi: 10.1007/s10384-024-01137-4. Epub 2024 Nov 16. PMID: 39549214.
21. Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of microbial keratitis with overnight corneal reshaping lenses. Optom Vis Sci. 2013 Sep;90(9):937-44. doi: 10.1097/OPX.0b013e31829cac92. PMID: 23892491.
22. Tapasztó B, Németh J, Kovács I, Nagy ZZ. Corneal inflammatory events during orthokeratology: analysis of 600 cases over two decades. Cont Lens Anterior Eye. 2026 Jan 16;49(2):102606. doi: 10.1016/j.clae.2026.102606. Epub ahead of print. PMID: 41547134.
23. Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999 Feb;15(1):85-90. doi: 10.1089/jop.1999.15.85. PMID: 10048351.
24. Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006 Dec;113(12):2285-91. doi: 10.1016/j.ophtha.2006.05.062. Epub 2006 Sep 25. PMID: 16996612.
25. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009 Mar;116(3):572-9. doi: 10.1016/j.ophtha.2008.10.020. Epub 2009 Jan 22. PMID: 19167081.
26. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012 Feb;119(2):347-54. doi: 10.1016/j.ophtha.2011.07.031. Epub 2011 Oct 2. PMID: 21963266.
27. Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014 Feb;157(2):451-457.e1. doi: 10.1016/j.ajo.2013.09.020. Epub 2013 Dec 4. PMID: 24315293.
28. Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, Lang E, Hemmati HD, Chandler SP; CHAMP Trial Group Investigators. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2023 Oct 1;141(10):990-999. doi: 10.1001/jamaophthalmol.2023.2097. Erratum in: JAMA Ophthalmol. 2023 Oct 1;141(10):1005. doi: 10.1001/jamaophthalmol.2023.4206. PMID: 37261839; PMCID: PMC10236322.
29. Di Meglio M, Giunta P, Rechichi M, Trofa A, Galantuomo G, Galantuomo N, Palmieri S, Pacente L, Salducci M. Treatment of progressive myopia with 0.01% Atropine in children and adolescents: an Italian 4-year follow-up study. Clin Ter. 2024 Sep-Oct;175(5):265-270. doi: 10.7417/CT.2024.5129. PMID: 39400089.
30. Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, Swaminathan M, Phuljhele S, Velpandian T, Sharma N. Atropine for the Treatment of Childhood Myopia in India: Multicentric Randomized Trial. Ophthalmology. 2021 Sep;128(9):1367-1369. doi: 10.1016/j.ophtha.2021.01.026. Epub 2021 Feb 2. PMID: 33545170.
31. Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, Lee SSY, Flitcroft DI. Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024 May;102(3):e245-e256. doi: 10.1111/aos.15761. Epub 2023 Sep 11. PMID: 37694816.

32. Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, Ng MPH, Young AL, Wu PC, Tham CC, Chen LJ, Pang CP, Yam JC. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report. Ophthalmology. 2024 Sep;131(9):1011-1020. doi: 10.1016/j.ophtha.2024.03.013. Epub 2024 Mar 16. PMID: 38494130.